Masimo Corporation
2852 Kelvin Avenue
Irvine
California
92614
United States
Tel: 949-250-9688
Website: http://www.masimo.com/
731 articles about Masimo Corporation
-
Masimo Corporation Board of Directors Authorizes Management to Evaluate the Separation of Consumer Business
3/22/2024
Masimo, a global leader in noninvasive monitoring technologies and audio products, announced that its Board of Directors has authorized management to evaluate a proposed separation of its consumer business.
-
Masimo to Present in 45th Annual Raymond James Institutional Investors Conference
3/4/2024
Masimo (NASDAQ: MASI) today announced that its management will participate in the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5, 2024 at 3:25 p.m. Eastern Time.
-
Masimo Reports Fourth Quarter and Full-Year 2023 Financial Results
2/27/2024
Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended December 30, 2023.
-
Masimo Announces the First FDA-cleared “Over-the-Counter” Fingertip Pulse Oximeter
2/13/2024
Masimo MightySat ® Medical Provides Clinically Proven Masimo SET ® Pulse Oximetry to Consumers for Medical Use Without a Prescription.
-
New Peer-Reviewed Study Finds That Masimo SET® Pulse Oximetry Measures Accurately on Both Black and White People Even During Low Perfusion
2/8/2024
Masimo (NASDAQ: MASI) today announced the findings of a retrospective, peer-reviewed study published in the Journal of Clinical Monitoring and Computing in which Dr. Vikrant Sharma, along with Dr. Steven J. Barker, Dr. William C. Wilson, and colleagues at Masimo performed a focused analysis of previously published data to evaluate the impact of low perfusion on the performance of Masimo SET® pulse oximetry across a variety of skin pigmentations.
-
Masimo Announces New Member of the Board of Directors - January 16, 2024
1/16/2024
Masimo (NASDAQ: MASI) announced today that Bob Chapek has been appointed to Masimo’s Board of Directors.
-
Masimo Announces Select Preliminary 2023 Financial Results and 2024 Guidance
1/10/2024
Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 30, 2023 and provided estimates for its full-year 2024 guidance.
-
New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation
12/11/2023
Masimo announced the findings of a retrospective study published in the Journal of Anesthesia in which Dr. Yu Jeong Bang and colleagues at the Samsung Medical Center, Sungkyunkwan University School of Medicine, in Seoul, South Korea, investigated the association of Masimo ORi™ and the arterial partial pressure of oxygen in 554 patients who underwent non-cardiac thoracic surgery during one-lung ventilation, making this study the largest to date on ORi.
-
Masimo to Present in Piper Sandler 35th Annual Healthcare Conference
11/27/2023
Masimo (NASDAQ: MASI) today announced that its management will participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am ET.
-
Masimo to Present in 2023 Jefferies London Healthcare Conference
11/9/2023
Masimo announced that its management will participate in the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 3:00 pm GMT.
-
Masimo Announces New Member of the Board of Directors
11/7/2023
Masimo announced that Rolf A. Classon has been appointed to Masimo’s Board of Directors.
-
Masimo to Report Third Quarter 2023 Financial Results after Market Close on Tuesday, November 7
10/24/2023
Masimo (NASDAQ: MASI) will release third quarter 2023 financial results for the period ended September 30, 2023, after the market closes on Tuesday, November 7, 2023.
-
Masimo ORi™ Granted De Novo as the First and Only FDA-Cleared Noninvasive and Continuous Parameter to Provide Insight into Hyperoxia Under Supplemental Oxygen
10/13/2023
Masimo (NASDAQ: MASI) today announced that ORi™, a noninvasive, continuous parameter designed to provide additional insight into a patient’s oxygen status in the moderate hyperoxic range under supplemental oxygen, has been granted a De Novo by the FDA.
-
Masimo Receives EU MDR CE Mark for LiDCO® Module for Hemodynamic Monitoring
10/9/2023
Masimo announced the CE mark, under the European Union Medical Device Regulation, for the LiDCO® board-in-cable module.
-
Masimo to Present in Wells Fargo Healthcare Conference
9/7/2023
Masimo (NASDAQ: MASI) today announced that its management will participate in the Wells Fargo Healthcare Conference on Friday, September 8, 2023 at 9:30 a.m. Eastern time.
-
Franciscan Missionaries of Our Lady Health System and Masimo Sign Multi-year, System-wide Monitoring Agreement
8/31/2023
Masimo and Franciscan Missionaries of Our Lady Health System, a 10-hospital system headquartered in Baton Rouge and serving communities throughout Louisiana and Mississippi, have signed a multi-year agreement to implement Masimo monitoring technologies system-wide.
-
Masimo Announces Full Market Release of Stork™ Smart Home Baby Monitor
8/23/2023
Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies, today announced the full U.S. market release of the Stork smart home baby monitoring system.
-
New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Elderly Patients Undergoing Gastrointestinal Surgery
8/21/2023
Masimo announced the findings of a prospective, randomized study published in Perioperative Medicine in which Dr. Yu Wang and colleagues at institutions in Shenzhen, Shaoguan, and Guangzhou, China evaluated the use of noninvasive, continuous Masimo PVi®, as part of goal-directed fluid therapy, to guide intraoperative fluid administration during gastrointestinal surgery on elderly patients by comparing it to conventional fluid therapy.
-
Masimo Reports Second Quarter 2023 Financial Results
8/8/2023
Masimo Corporation announced its financial results for the second quarter of 2023, ended July 1, 2023.
-
New Study Finds That Masimo SedLine® Patient State Index (PSi) Has the Potential to Improve Brain Monitoring for Patients Sedated with Dexmedetomidine
8/7/2023
Masimo (NASDAQ: MASI) today announced the findings of a study published in Frontiers in Neuroscience in which Dr. Lichy Han and colleagues at Stanford University evaluated the ability of Masimo SedLine® brain function monitoring to assess the sedation levels of patients undergoing drug-induced sleep endoscopy (DISE) with dexmedetomidine – a sedative with numerous advantages.